Good morning, and thank you for joining us. This is Kevin Miller, Chief Financial Officer of RCM Technologies. I am joined today by Bradley Vizi, RCM's Executive Chairman. Our presentation in this call will contain forward-looking statements. The information contained in the forward-looking statements is based on our beliefs, estimates, assumptions, and information currently available to us, and these matters may materially change in the future. Many of these beliefs, estimates, and assumptions are subject to rapid changes. For more information on our forward-looking statements and the risks and uncertainties and other factors to which they are subject, please see the periodic reports on Forms 10-K, 10-Q, and 8-K that we file with the SEC, as well as our press releases that we issue from time to time. I will now turn the call over to Bradley Vizi, Executive Chairman, to provide an overview of RCM's operating performance during the quarter. Thanks, Kevin. Good morning, everyone. Consistent with our prior update, the business cadence continues to accelerate as we move through the year. As such, the fourth quarter will be our strongest, and we expect to exhibit EBITDA growth year-over-year. Also of note, the outlook for 2024 and beyond is bright. Our ability to parlay our high-value capabilities into long-term partnerships, where we continue to deliver increased value into strategic accounts, has taken hold. We believe our collection of high-value capabilities is unique to the, to the marketplace, serving as a key differentiator for which to land and expand. Internally, we continue to build on our unique structure that fosters innovation and increased depth of penetration within each of our end markets, while increasingly strengthening points of collaboration between groups. Our ability to continue to execute this strategy will, will increasing... With increasing success, will further fuel growth, future growth into our secular end markets for years to come. Since we last spoke, progress has been made across each of our divisions that I am excited to discuss in more detail, starting with our healthcare division. The school year is off to a strong start for our healthcare team. Notably, we continue to add new school accounts while growing our presence within our existing client base. We attribute ongoing success to the goodwill we continue to build upon in this end market, underpinned by our commitment to supplying highly qualified healthcare professionals to education institutions and other healthcare facilities nationwide. Behavioral health continues to drive our business at an increasing rate, and we believe we are in the early innings of this much-needed upgrade to our nation's social infrastructure. Also, with increased demand for behavioral health services comes the opportunity to further service our clients with other critical healthcare needs, cementing our status as a partner, not just another vendor, which is core to the RCM business model. RCM Healthcare's tailored staffing solutions, coupled with a rigorous selection process, have bolstered our reputation in the education domain, solidifying our status as the leader in this segment of the market and the gold standard for treating our nation's youth. As we move forward, we remain committed to sustainable growth, innovation, and the highest standard of service. We anticipate further expansion into new markets and the development of cutting-edge staffing solutions that meet the evolving needs of the healthcare industry. Our dedication to improving the quality of healthcare services positions us to continue exceeding the expectations of our stakeholders, driving value for our shareholders, and positively impacting healthcare and education in the years ahead. The ability to build good businesses while serving a critical need in society and strengthening our communities resides at the core of our company's values. Our Life Sciences and Information Technology group continues to emerge as a shining star in the portfolio. Though the macroeconomic landscape in information technology was challenging in 2023, including budget reductions across several sectors, from high tech to financial services, our decision to continue investing in market segments demonstrating secular growth has paid off. The group's overall EBITDA contribution is up nearly 55% year-over-year. As we continue to double down on the winning formula, just this last quarter, we have expanded our Life Sciences practice in regulatory compliance, ERP design, and implementation. We are building out our organizational change management practice, which will further allow us to support our clients across their entire business landscape, while providing improved value through our current delivery models. We continue to see positive trends entering the last leg of 2023 and have a positive outlook for 2024. In Engineering, Energy Services' strong execution demonstrates increasing leverage in the model, highlighted by continued delivery of milestones on time for several world-class projects, resulting in client satisfaction and solid gross margins. Technical highlights include successfully completing Site Acceptance Tests as part of an E-House high-voltage application utilizing the IEC 61850 protocol. In addition, we were approached to pursue an offshore high-voltage GIS substation with a large international operating OEM as part of a potential long-term partnership. Also, several vital deliverables were executed on time for a critical infrastructure project with a major utility client in New York. This project represents a significant milestone in the clean energy transition in the Northeast United States. In Europe, our newly established office in Germany received recognition as a strong technical partner to support turnkey projects that will transfer the power supply to a carbon-free electric grid. We are in the late stages of negotiation for our second major project award, demonstrating increasing client confidence. To serve the increased demand for EPC projects in 2024 and beyond, energy services will further expand its EPC capabilities in Europe and North America. We believe the recent addition of a high-profile industry veteran to the RCM Energy Services leadership team will accelerate the award and execution of EPC projects in the United States and further enable us to prudently evaluate new regional areas such as South America. RCM Thermal Kinetics continues to execute detailed engineering contracts for distillation, evaporation, and dehydration technologies employed in the carbon capture and sustainable aviation fuel markets. On the equipment side, the office is currently executing three concurrent projects for a zero- carbon chemical manufacturing customer, primarily using evaporation and crystallization technologies. The main driver for successfully awarding the orders to RCM Thermal Kinetics is the advanced energy integration techniques utilized in the design. The RCM Thermal Kinetics engineering expertise related to energy integration of extensive chemical processes has an obvious tie-in to these environmentally responsible projects. It is why customers are standardizing on RCM Thermal Kinetics as their process design and equipment supplier. We recently opened RCM Thermal Kinetics testing facility. It is beginning to gain traction. In the coming weeks, two purchase orders are expected from clients requesting process feasibility and product profile testing. The office has greatly strengthened ties to local universities to support staffing of the testing lab through chemical engineering internships. The customer support offered through process testing has a track record of receiving additional project orders. It provides the benefit of process risk reduction for both the client and RCM Thermal Kinetics. We expect lab utilization to ramp up in 2024 for new customers and testing related to existing customer projects. In addition to our lab, the engineers are now working on the design of a 30-gallon crystallization pilot plant. RCM Thermal Kinetics receives a large number of crystallization inquiries. More than any other technology, crystallization projects benefit from the ability to conduct robust piloting trials to produce product samples for our customers. The current schedule would have this pilot testing service ready for client use in May 2024. RCM Thermal Kinetics recently presented at the Advanced Bioeconomy Leadership Conference in San Francisco. The team has been a member of ABLC for many years and benefits from building relationships with emerging companies interested in developing new processes that require our technologies. Many of our customers today were cultivated from ABLC meetings over the past 10 years. The sales team has also attended the Aluminum USA Show. RCM Thermal Kinetics has successfully supplied environmental equipment to aluminum production plants in the United States. The team remains focused on continuing its emergence as a responsible and sustainable chemical process design market leader. As for our aerospace team, the growth and recovery we expect mid-year has begun to materialize in the third quarter, with nine new clients, resulting in our weekly rev rate and headcount increasing, nearing our historical numbers. We still believe we have the potential to close three more new clients before the end of the year, totaling 12 for 2023. We also continue to increase the number of hires quarter-over-quarter, with a total of 40 in the third quarter, compared to 30 in the second quarter of 2023. This continued expansion includes new clients in defense, including sea vessels, land vehicle programs, and new vertical lift customers. Expanding existing and new clients with our core expertise and new arenas provides us much-desired depth and breadth of the organization and firmly positions us for 2024. As the management team within some of our existing clients continues to change, we have utilized our long-term relationships, reputation, and expertise to stay relevant. We believe we will see traction on one of our most significant awards for a design center well into 2026. We continue to market our digital conversion expertise and methodology within aftermarket and our model-based design prowess, which now expands across multiple clients throughout the United States. We have multiple contracts with large OEMs finalized and executed in 2023. We also await a large, all-encompassing RFP from one of the largest defense contractors, providing a vehicle to support this client across all engineering and aftermarket disciplines. We will continue to expand our reach with these clients and prioritize these types of engagements in 2024. We continue to market the S-F actor, which broadens our reach beyond S1000D publications into S2000M material management, S3000L logistics support analysis, S4000P maintenance, and S5000F in-service data feedback. We are happy to report that we have our first launch client, which we will support in these expanded areas beyond technical publications. We have reorganized the aftermarket arena to provide opportunities in other areas for our team members, and we have increased our business development team for the first time in two years. We are excited about the opportunities that this team has already uncovered. Before turning the call to Kevin, I would like to reiterate the financial expectations provided during the third quarter. We continue to anticipate EBITDA growth during the fourth quarter, a resumption toward our long-term objective, which is also in line with our expectation for 2024. I also want to reiterate that as a general policy, we do not give guidance. However, we felt a more granular expectation as we close the year would be appropriate, given the advanced macroeconomic noise in the marketplace. I will return the call to Kevin to discuss the Q3 2023 financial results in more detail. Thank you, Brad. Regarding our consolidated results, gross profit for the third quarter was essentially flat year-over-year, with $17.3 million in Q3 2023 versus $17.4 million in Q3 2022, twenty-two. Healthcare gross profit in Q3 2023 was $7.5 million versus $9.0 million in Q3 2022. There were primarily two reasons for the quarterly decline in healthcare gross profit. First, we believe that Q3 2023 was our first quarter where we derived zero COVID-related revenue. To give this perspective, if we remove the estimated impact of COVID, we saw our school revenue grow by approximately 25% in September 2023 compared to September 2022. We experienced similar results in October 2023. COVID also impacts our non-school revenue comp. Second, we deliberately culled the services provided to a multi-location continuing care client in the five boroughs of New York City and Long Island. At the beginning of COVID, we acted as an emergency VMS to this client. As the gross margins from the non-direct revenue shrunk post-COVID, we decided that the contribution margin on that revenue was insufficient for our return model. On a year-over-year basis, our quarterly revenue decreased by $2.1 million from this client. If we compare Q3 2023 to Q2 2023, this client decreased by $1 million sequentially. The decrease in this low-margin business helped us grow sequential gross margin to 30% in Q3 2023 versus 27.6% in Q2 2023. We grew engineering gross profit in Q3 2023 by 5.2% over Q3 2022. The growth in gross profit was primarily driven by increased project activity in our energy services group and getting our engineering gross margin closer to target levels. Our gross margin in Q3 2023 was 25.0%, a significant sequential improvement from Q2 2023 gross margin of 22.9%. We continue to see outstanding results from our Life Sciences and IT group, with 38.4% quarterly growth in gross profit year over year. We are seeing fantastic results as we drive more revenue through our high-value, high-margin managed service offerings. We hope there is another gear we can get to in Q4 2023. As we look to our fourth quarter of 2023 and our fiscal 2024, we expect all three segments to show good results, with growth in Consolidated Adjusted EBITDA. We estimate Adjusted EBITDA in Q4 2023 between $7.6 million and $8.2 million. Also, in Q4 2023, we estimate consolidated revenue between $70.0 million and $74.0 million, with a similar gross margin profile to Q3 2023. More granularly, we estimate Life Sciences and IT revenue between $11.0 million and $11.5 million. We estimate Engineering revenue between $21.5 million and $23.0 million. We estimate Healthcare revenue between $37.5 million and $39.5 million. Since we have discussed some variability and seasonality in our healthcare segment, we thought it would be helpful to discuss our weighted average school days in 2023. Q1 2023 was approximately 55 days. Q2 2023 was approximately 45 days. Q3 2023 was approximately 27 days. Q4 2023 is estimated as about 51 days. So that's about a 7% decline in school days when comparing Q4 2023 to Q1 2023. While we haven't penciled our first budgets yet, we expect a similar cadence to school days in 2024, except one or two days may shift from Q1 to Q2. We'll give 2024 estimates on our next call as, as we have our budgets ready for the year. As for fiscal 2024 Adjusted EBITDA, we will be, we will be highly disappointed if we don't see at least low double-digit growth. Our internal goals will undoubtedly reflect a much higher percentage. We are optimistic about growing all three segments in fiscal 2024 and beyond. This concludes our prepared remarks. At this time, we will open the call for questions. If you would like to ask a question, please press star one on your telephone keypad. Again, to ask a question, press star one on your telephone keypad. Our first question is going to come from Alex Rygiel with B. Riley. Your line is open. Thank you, gentlemen. Very nice quarter, and appreciate the added, guidance there. Super helpful. Couple quick questions for you here. First, as it relates to Healthcare, what was your revenue from schools in the third quarter? The schools was $17.4 million. Thank you. And then your balance sheet's incredibly strong, and you talked a bit about expanding into new staffing markets. So maybe Brad, you could go a little bit deeper on that? Yeah, look, you know, as alluded to in the prepared remarks and been pretty consistent with our dialogue the last couple of years, you know, we have these businesses at a point where we have a lot of confidence in a number of places in the portfolio. So, we're in a position to be opportunistic with respect to deployment of capital and expansion into new adjacencies. You know, we're not looking to go greenfield into any new areas per se, simply because there's plenty of opportunity to build on, you know, the core of what we do. So, you know, naturally, our first, you know, inclination is to do it organically by bolting on talent. And to the extent that there's opportunity inorganically, you know, with respect to M&A, you know, we're going to react opportunistically, and would anticipate it being more of a bolt on than any type of a major transformational platform type acquisition. So I don't know if that answers your question sufficiently. Definitely does. And then as it relates to the engineering segment, can you talk a bit about the backlog there and the outlook for 2024? Yeah, we feel pretty good about what's going on in Engineering. You know, like we have increasing momentum with respect to the metrics that we track. It's almost like a hybrid pipeline and backlog metrics, given that we feel is appropriate, given the mix of our business. You know, it continues to grow. So, you know, we're anticipating good things, but you know, engineering inevitably, given the nature of the project work, you know, it could certainly deviate, but we do not expect anything substantial. It's a question in our minds as to whether or not it's going to be, you know, a pretty good year, you know, to a very nice increase year-over-year. And then lastly, as we think about the first quarter of 2023, you mentioned that there were 55 school days, and then you mentioned that in the third quarter there were 27, and you had no sort of COVID-related revenue. I guess my question here is, as we think about the fourth quarter being 51 days, and that's down 7% from the first quarter, in the first quarter, was there any COVID-related kind of legacy revenue in that first quarter? Yes, certainly. Yeah, but I think, you know, we gave pretty clear, you know, pretty good guidance for Q4, right? So, we do not expect any COVID-related revenue in, you know, in Q4. And so far, what we've seen, at least in October, is if we look at our schools, okay, which is our core business in Healthcare, obviously we do a lot of work outside of schools, but at the end of the day, you know, we're a Healthcare school business. That's our core business in Healthcare, right? That grew 25% in September, and it grew 25% in October, and we really think we can build from there. Great. Thank you very much. Our next question is going to come from Ben Andrews from Andrews Capital Management. Your line is open. Hey, good morning, guys. Hi, Ben. Couple of balance sheet type questions, if I may. Understanding the transit account, I always thought it was subcontractor related. Is that have a specific industry or segment flare? Is that your Engineering segment or primarily, what is that tied to? Yeah, you got it right. It's tied to Engineering and mostly to EPC contracts. So we have several large EPC contracts where we do the E and the P, but we don't do the C. You know, we don't take inventory of the equipment. The equipment, you know, we purchase the equipment, but it goes straight from the OEM to the client. So we never take, you know, inventory of that equipment. And so a lot of that is, you know, advanced payments for equipment and construction. Okay. And, so, what, ballpark, is the revenue stream going to those subcontractors? Well, in terms of the, it's pretty significant, right? So we have. But, it's all pass through. So, Right. So that doesn't show up in your income statement, but then their liabilities or their equipment will show up on your balance sheet? No, not the equipment. The equipment never hits our balance sheet, Ben. Essentially, you know, because we never take inventory of it, it's never our equipment. It's at all stages owned by our client. So we're basically moving the equipment and paying for the equipment, but we don't own it. So the equipment itself never hits our balance sheet. So, you know, we get a payment in from the client, and then, you know, we get like milestone payments, essentially. And we certainly manage those contracts so that we're paid up front, so we're not putting out, you know, huge sums of money for equipment and construction. So the money comes in, you know, we order the equipment, we do the work, and then eventually we pay for it. And then, you know, more money comes in because these are typically multi-year contracts. They go for, from anywhere from two to five years. Okay. So, a liability then would already be revenue earned by that subcontractor? Not necessarily. You know, some of it may be earned, but some of it may not be. Okay. Okay, so you can book out further than 12 months? Yeah. Obviously, we're not booking any revenue until we actually earn it, right? Based on the progress of the contract and based on the amount of engineering that's been done, right? So, you know, we do make a small percentage on the equipment, you know, and the construction as well, and that also hits our income statement as revenue. Okay. Regarding share issuance, it looks like there was a fairly large share issuance in the quarter, you know, maybe 10% of the market cap. And it was clearly larger than any vesting schedule of, you know, what was already out there in your queues. What went on in the quarter? Yeah, I don't have the exact share numbers in front of me, Ben, but I believe that we had about 100,000 shares issued to probably 20 employees under, you know, long-term time-based restricted share awards. Maybe I- The exact number. Yeah, maybe I- Right. Maybe I read it wrong then, because I thought it was 800,000 shares. No, definitely not. Because you finished last quarter a little under 8 million shares, and I thought I saw 8.8 million shares outstanding right now. No, it's 7.8, Ben. Oh, okay. I'm sorry. It's not a type of- I misread it. Yeah. Yeah. Okay. All right. Sorry. I have the... No problem. I have the queue in front of me. As of yesterday, we had $7,832,393 outstanding. Okay. Thank you, guys, for all your hard work. Appreciate it. Thank you, Ben. Bye-bye. Thanks, Ben. Our next question is going to come from Bill Sutherland with Benchmark. Your line is open. Hi, Bill. Hi. Hi, Bill. Hey, guys. Hey, following up on Ben's question on the shares, is that still at the top of the capital deployment list for you guys going forward? Yeah. Yeah, look, Bill, I mean, you know, we, you know, always pretty much anticipate having some form of a buyback in, right? Naturally, as, you know, we take in shares and, and volume decreases, you know, the magnitude of buyback is inevitably going to wane. You know, however, you know, as you see, we continue to be active. You know, we continue to be, you know, quite optimistic about our ability to deliver value at the company. And so, you know, it's, it's safe to assume we're very much committed to deploying capital, you know, through that medium. Okay. It's, it's certainly been very effective. Hey, Brad, zooming out a little bit on Engineering and thinking about Aerospace, getting back on it, on its feet and just the opportunities, particularly as you broaden it out into Defense, but the other areas as well, I mean, how should we think about the kind of intermediate growth for that group overall, Engineering? Yeah. You know, we're quite optimistic about the future of Engineering. You know, you almost look at all three segments, all three units. With respect to energy services, we continue to gain traction. You know, we have a number of very large long-term partners, as we continue to build confidence, project after project. In some instances, it's a matter of how much we can take on. So really going back to the core of that strategy, leading with, you know, technical capabilities that we think are very much differentiated in the marketplace, you know, with respect to, you know, kind of, you know, our track record and the talent that we've assembled. And from there, naturally, as you become a preferred partner, you know, the attachment of incremental work is. It can be very substantial. So, you know, what you're really seeing there, you know, in the case of, you know, our, you know, our energy services group is, you know, really, you know, years have come. We're at a bit of a tipping point with respect to... compounding of years of goodwill and kind of, you know, earning that trust. So we actually have very high expectations going forward for that business. You know, with respect to Aerospace, again, a very strong growth orientation to it. You know, had a bit of a setback very late last year, last two weeks or so of the year. You know, very happy with how the team dealt with it and rebounded, adding incremental clients, you know, several of which are very significant and present meaningful opportunity to expand within those accounts. So, you know, again, in terms of the upside in that business, you know, we're quite optimistic, you know, in 2024 and beyond. And then finally, with respect to process, you know, again, a very, very strong technical capabilities and team. You know, we've clearly invested in that business, making sure they have all the tools that they need, you know, to continue to build on their reputation and ultimately the financial performance of that business. You know, inevitably there will always be an element of lumpiness there. Yeah, that will be difficult to forecast. You know, however, it is a very IT intensive part of our portfolio and, you know, we get paid for that intellectual property. And so, you know, it's a, you know, economically very attractive model. So, you know, with respect to saying, you know, this quarter, you know, is going to be an excellent quarter versus, you know, call it Q3 or Q4, that one's probably the most challenging. You know, however, the returns are very robust. You know, the team is as strong as it's been. The reputation is very much intact, and we believe we continue to you know build on that, and so we are you know optimistic for its performance as well. But very specifically, we think that group has troughed, you know, having you know finished up a couple of large projects and activity is you know starting to go in the right direction. So is that, is that the thinking, as you look at your fourth quarter range, likely range for revenue, and looks like you're quarter-on-quarter flat to maybe off a little bit? So is that just the completion phase and your new, your new work starts to ramp in the first quarter next year? Yeah, no question, there's a little bit of that. But Kevin, do you want to go into very specifically, you know, the breakdown within engineering and how we're thinking about that sequential cadence? Sure. I mean, you know, it is difficult to project as, you know, as Brad said, but we believe what we believe we'll see in Engineering next year, you know, is a slow sequential uptick, you know, as we move throughout the year, right? So we would expect Q1 revenue to be higher than Q4, you know, Q2 to be higher than Q1, and so forth. You know, you know, I'm not sitting here projecting any big, you know, giant jumps in any particular quarter, but what I would like to see is, you know, single digit sequential growth each quarter, right? Mm-hmm. With obviously there being some upside, depending on what happens with, you know, all the different irons we have in the fire. As you've, you know, you've been covering us a long time, Bill, so you've seen how, you know, engineering can really jump in a quarter and stay up for a while, depending on what projects we have. But, you know, in terms of, you know, expectations and what we expect to happen, you know, I would expect to see a sequential uptick each quarter, and then obviously hope to see if we can really boost that with a couple of big projects. Gotcha. Okay. Makes total sense. So, what's the other thing I was gonna ask you? You know, we need to continue to work on our margins because it's not just about adding revenue, right? Yeah. It's about adding quality revenue and gross profit that, you know, that gross profit dollars that are driving our return model. Mm-hmm. Okay. Back to Healthcare just for a second. I was thinking about the comments, Brad, you made about behavioral health really taking off. Is it, I mean, where are you in terms of its importance to you? In other words, is it becoming a meaningful percentage of revenue yet, or you're still just starting that process? I think it's the majority of the business at this point. And, you know, frankly, you know, we anticipate, you know, seeing it accelerate. You know, as you know, we've been pretty excited about the story and positioned ourselves for it, accordingly, the last couple of years. You know, I wouldn't call it on the comm. You know, there's certainly a bit of an increasing drumbeat, but, you know, I think, you know, call it the last, you know, call it nine, 12 months. I think you are seeing a meaningful increase, you know, and we anticipate that that activity is continuing to go in the right direction. I think naturally you think about... Some of the drivers of this from a macro perspective, you know, oftentimes investment, you know, behind this type of—these type of social infrastructure initiatives are going to come on a lag. And we think that's exactly what we're seeing. So, you know, very exciting part of the portfolio, no question about it. You know, we think that there's plenty of upside there. So, and, you know, we're certainly willing to keep everybody posted as that continues to crystallize. Okay. And have you- I would just add to that, Bill, that you know, three years ago, our behavioral health revenue, three, four years ago, was primarily coming from 2 clients, you know. So today we have well over 30 that we're providing behavioral health services to. And as you know, when I look at this behavioral health market for RCM, you know, we're still in the first or, you know, first inning, second at best, right? Yeah. So we just think there's amazing potential there. We think we can, you know, we just think there's so much growth out there. Now, obviously, there's a lot of competition. There's a lot of other companies that are going after this business, but there's just, there's a lot of business out there for us to grab. And we think our team is stellar, and we're really excited to grab it. You know, there's only so much you can grab in one school year, because once the contracts are set for that school year, you know, you, you're not gonna typically add, like, you know, a $5 million client in the middle of the school year. But we have a lot of potential to build, you know, with the 30 schools that—approximately 30 schools that we're providing behavioral health. And then hopefully when we get the next school year, we'll have, you know, we'll add another 20, another 30, we'll see. It's a really exciting business to be in and- Mm-hmm. We're pumped about it. Roughly how many schools are you in now, total, year? Probably about 70, where we're active, roughly. Okay. Good. Okay, thanks for all the color, guys. Good work. Once again, if you would like to ask a question, please press star one on your telephone key. Okay, it looks like we have a question from Frank Kelly. Your line is open. Good morning, gentlemen. Great, great quarter. Great quarter. Thanks, Frank. In particular, life science is heading to 40%. Phenomenal. Absolutely outstanding. And, love to, love to see top line growth there, and that, that, that unit take over. Switching over to the balance sheet on actual, you know, trade accounts receivable, what... Can you shed some light on there? It just, just seems to see that we're losing significant traction since since our last call and, and since year end, 12/31/2022. Sure. I can, I can speak about that, Frank. You know, we, we talked a little bit on the, on the last call. So, you know, the receivables relative to where the revenue right now is, are, they're just too high, the trade receivables, period. And, you know, we're doing a lot of different things to, you know, to, to, to get them down and get our DSOs to a, to a, to a better level. But as, as I think you, you know, because you, you've fought these battles before in your career, you know that when you get into Q3, because our, because our, revenue is somewhat backloaded, you know, into September, right? Because of the schools being closed in June and July, we're always gonna have sort of a wacky looking receivable, you know, slash DSO in Q3, because of the, you know, cadence of how the revenue you know hits the income statement. Obviously, you're not gonna have any receivables collecting, you know, in October relative to September, right? Or at least very little. So that's one factor in Q3. If you compare Q3 to Q4, you know, to be really frank with you, we you know we had a little bit of a different revenue composition, where we had some clients that just paid a lot faster than we do today. Particularly when you start talking about some of the COVID-related revenue, that money was just coming in very, very fast. So the DSOs in Q4 are historically low for us. Certainly a goal for us to get back to those levels where we were in Q4, and we're working like hell to get there. But those numbers are historically low. And then if you look at the receivables today and the DSOs today, you know, we have a couple of clients that are really good clients, high margin clients, particularly in the Life Sciences space, that just pay a little. Like that industry, it's not uncommon to get contracts where these big companies say, "You know, payment terms are 90 days, take it or leave it. If you want the business, you gotta wait 90 days," right? We have a few clients like that, that are fantastic clients, very profitable, even with, you know, the high DSOs, they, they fit our return model very, very well. So that's one aspect that's contributing to, you know, the higher DSOs. When you flip over to the EPC clients, a lot of the EPC clients, and some of the utilities are also slow payers, but the overall cash flow aspect of those engagements are excellent. It's just that when you look at the trade DSOs, you, you, you just see they don't look great, but the overall cash economics of those clients are outstanding. You know, so you've got a couple of factors going on, but I can assure you that we are working very hard to get DSOs at a much lower level where they were in, you know, Q2 and Q3. Stay tuned. Do we, Kevin, stay tuned? Do we have? You said you were talking about DSO numbers, so you know where they are. Where were they in Q2 and Q3? Well, you know, obviously, people calculate DSOs differently, right? But you know how I calculate them. They were 84 in Q2, they were 90 in Q3, they were 79 in Q1, and they were at an all-time low in Q4 of 66. So we... Right. We need to get, you know, some way, somehow, we need to get them a lot closer to 70. Right. 'Cause I think if we look on the flip side of that, on expending capital against debt, you know, there could be a pickup of, you know, as much as over $1 million, $1.2 million EBITDA, if we collect those and turn them down into against the line, right? Well, it's not gonna impact EBITDA. Okay. It's really the matter of impacting our interest costs, right? But- Well, interest costs, like, they're included in EBITDA, right? Am I standing corrected or no? Yeah, no. Yeah. Interest before earnings before interest, so no. It doesn't impact interest, but your point is a good one. We are very, very focused on cash flow, and the most important measure that we look at this company is return on, you know, is return on equity. Like, that's the most important thing, and we pride ourselves in having a very high return on equity, and this is an important component to it. Great. Keep it up. Thanks for the, Thanks, Frank. The info. It looks like Bill Sutherland had a follow-up question. Bill, your line is open. Yeah. I was curious, Kevin, about the tax rate in the quarter and what to think about for the year. Yeah, we had a one-time discrete, you know, tax benefit in Q3 that helped us out, but it's just a Q3 thing. I think when you start looking at Q4, you're probably looking at consolidated taxes, you know, 28%-29%, roughly. Okay. But I think we're gonna have a discrete item that's gonna work the other way. It's gonna bump it up a little bit in Q4. You know, long term, I think 28% is a pretty good rate for you to use in your model. Okay. Thanks again, guys. Have a good one. And once more, if you would like to ask a question, please press star one. Okay, doesn't look like we have any more questions, so I'll turn it back over to you for any closing remarks. Thank you for attending RCM's third quarter conference call. We look forward to our next update in 2024. This concludes your call. You may now disconnect.